Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Gains from Investment Securities: 2012-2024

Historic Gains from Investment Securities for OptimizeRx (OPRX) over the last 9 years, with FY2024 value amounting to $1.8 million.

  • OptimizeRx's Gains from Investment Securities fell 9879.52% to $5000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $503000.0, marking a year-over-year decrease of 4164.73%. This contributed to the annual value of $1.8 million for FY2024, which is 1869.95% up from last year.
  • OptimizeRx's Gains from Investment Securities amounted to $1.8 million in FY2024, which was up 1869.95% from $1.6 million recorded in FY2023.
  • OptimizeRx's Gains from Investment Securities' 5-year high stood at $1.8 million during FY2024, with a 5-year trough of $121129.0 in FY2021.
  • For the 5-year period, OptimizeRx's Gains from Investment Securities averaged around $993860.0, with its median value being $1.3 million (2022).
  • As far as peak fluctuations go, OptimizeRx's Gains from Investment Securities crashed by 1371.96% in 2021, and later surged by 97890.76% in 2022.
  • Annual analysis of 5 years shows OptimizeRx's Gains from Investment Securities stood at $140390.0 in 2020, then decreased by 13.72% to $121129.0 in 2021, then surged by 978.91% to $1.3 million in 2022, then grew by 18.99% to $1.6 million in 2023, then grew by 18.7% to $1.8 million in 2024.
  • Its Gains from Investment Securities stands at $1.8 million for FY2024, versus $1.6 million for FY2023 and $1.3 million for FY2022.